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Abstract: Marine pyridoacridines are a class of aromatic chemicals that share an 11H-
pyrido[4,3,2-mn]acridine skeleton. Pyridoacridine alkaloids display diverse biological 
activities including cytotoxicity, fungicidal and bactericidal properties, production of 
reactive oxygen species (ROS) and topoisomerase inhibition. These activities are often 
dependent on slight modifications to the pyridoacridine skeleton. Here we demonstrate that 
while structurally similar to neoamphimedine and amphimedine, the biological activity of 
deoxyamphimedine differs greatly. Deoxyamphimedine damages DNA in vitro 
independent of topoisomerase enzymes through the generation of reactive oxygen species. 
Its activity was decreased in low oxygen, with the removal of a reducing agent and in the 
presence of anti-oxidants. Deoxyamphimedine also showed enhanced toxicity in cells 
sensitive to single or double strand DNA breaks, consistent with the in vitro activity. 
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1. Introduction 
Marine pyridoacridines are a class of planar aromatic molecules with an 11H-pyrido-
[4,3,2mn]acridine skeleton that show affinity for DNA. Great interest in this class of compounds is 
evident from numerous synthetic studies and total synthesis reports [1-8]. In general, pyridoacridines 
are cytotoxic and some of them possess potent anti-viral, anti-fungal, anti-bacterial, anti-tumor and 
anti-parasitic activity [9]. For the majority of this class, cytotoxicity has been shown to be due to 
DNA-binding properties, topoisomerase inhibition and the production of reactive oxygen species 
(ROS) [9]. 
Deoxyamphimedine, neoamphimedine and amphimedine are pyridoacridines isolated from 
Xestospongia sponges collected in the Philippines and Micronesia (Figure 1). We previously reported 
that neoamphimedine is cytotoxic via topoisomerase 2-dependent DNA aggregation/catenation, while 
amphimedine is relatively non-toxic [10]. During the analysis of the bioactivities of neoamphimedine 
and amphimedine it was observed that deoxyamphimedine cleaved DNA in vitro in the absence of 
topoisomerase (1 or 2) [11]. In this paper we describe the ability of deoxyamphimedine to damage 
DNA through the production of ROS.  
Reactive oxygen species, although produced during normal aerobic metabolism in mammalian 
cells, have been implicated in cell and tissue damage [12,13]. Free radicals produced by oxidative 
processes can attack DNA at bases or sugars, causing primarily single strand breaks, as well as, 
secondary double strand breaks and abasic sites [14-16]. Quinone functions are capable of redox 
cycling. One electron reduction of the quinone forms reactive semiquinones, allowing electron transfer 
to other species [17]. Higher redox potential of quinone molecules has been correlated with increased 
DNA cleavage [18]. This study demonstrates the cytotoxicity of deoxyamphimedine, its ability to 
intercalate and damage DNA and the attenuation of this activity when the generation of ROS  
was inhibited. 
Figure 1. Chemical structures of: A) deoxyamphimedine, B) neoamphimedine and  
C) amphimedine. 
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2. Results and Discussion  
2.1. Cytotoxicity in Cultured Mammalian Cell Lines 
Pyridoacridines are often cytotoxic in cultured cell lines. Deoxyamphimedine was originally found 
to be toxic in HCT-116 (human colon tumor) cells and shown to have enhanced toxicity (4-fold) 
against the EM9 strain of Chinese hamster ovary (CHO) cells, which are deficient in single strand (ss) 
DNA break repair when compared to the wild type AA8 strain [11]. The sensitivity observed in 
ssDNA break repair deficient cells typically correlates with compounds having topoisomerase 1 or 
reactive oxygen species (ROS) mediated DNA cleavage [19-21]. We further tested deoxyamphimedine 
in a panel of other cultured cell lines previously tested with neoamphimedine and amphimedine [10]. 
The IC50 values of deoxyamphimedine are reported in Table 1.  
The observed IC50 values were typically slightly lower than those reported for neoamphimedine, 
while amphimedine was not toxic up to 100 µM tested [10]. Deoxyamphimedine and neoamphimedine 
were cytotoxic in every tumor cell line examined, indicating their potential as anti-cancer drugs. 
Deoxyamphimedine was almost equally toxic to the A2780wt and its paired multi-drug resistant cell 
line, A2780AD, which exhibited resistance to doxorubicin (33 fold), M-AMSA (8 fold), and taxol (15 
fold) when compared to the A2780wt cell line. The lack of significant fold difference for 
deoxyamphimedine in the A2780 cell lines indicates that it is likely not a substrate for the multi-drug 
resistant pump that often impedes the efficacy of cancer drugs in chemotherapy. In repeated 
experiments, deoxyamphimedine again was selectively more toxic to the mutant CHO cell lines, EM9 
and xrs-6, than the wild type (AA8). The EM9 cell line has enhanced sensitivity to topoisomerase 1 
poisons and ROS that cause DNA single-strand breaks. Sensitivity observed in the xrs-6 cell line is 
often associated with compounds that generate DNA double strand breaks via topoisomerase 2 or high 
amounts of single strand DNA cleavage [22]. These data confirm DNA strand breakage as a 
contributing mechanism of deoxyamphimedine cytotoxicity. 
Table 1. Cytotoxicity of Deoxyamphimedine. 
Cultured Mammalian Cell Line IC50 in µM 
Human melanoma, SK-mel-5 5.5 
Human epidermoid-nasopharyngeal cancer, KB 3.8 
Human breast cancer, MCF7 5.9 
Human ovarian cancer-wild type, A2780wt 0.3 
Human ovarian cancer-multi-drug resistant, A2780AD 0.4 
Chinese hamster ovary, CHO wild type, AA8 13.7 
CHO-double strand (ds) DNA break repair deficient, xrs-6 4.2 
CHO-single strand (ss) DNA break repair deficient, EM9 3.8 
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2.2. Deoxyamphimedine Intercalates DNA 
Many pyridoacridines have shown binding affinity for DNA, and this binding often correlates with 
the observed cytotoxicity [9]. To measure DNA intercalation, deoxyamphimedine was compared to 
amphimedine and neoamphimedine, in an ethidium bromide (EtBr) displacement assay. 
Deoxyamphimedine exhibited potent DNA intercalation, displacing 50% of EtBr at 1 µM, while 
neoamphimedine required approximately 100 µM to displace 50% of EtBr. Amphimedine was unable 
to significantly displace EtBr at concentrations up to 100 µM (Figure 2). These results suggest that 
deoxyamphimedine has a higher affinity for DNA than its analogs, as might be expected from its 
positive charge. 
Figure 2. EtBr displacement by the amphimedines as a measure of DNA intercalation. 
Values are the average of n=4 ± SD. 
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2.3. Deoxyamphimedine Cleaves DNA Independently of Topoisomerase 1 or 2 
 
DNA intercalators often interfere with DNA metabolizing enzymes, such as the topoisomerases. 
Therefore, in vitro analyses to evaluate the potential importance of the topoisomerase enzymes for 
DNA damage were performed. 
The topoisomerase 1 and 2 DNA cleavage assays (Figure 3) showed that amphimedine did not 
inhibit either of the topoisomerase enzymes, nor did it increase the amount of cleaved DNA observed 
in the gel. Neoamphimedine, as previously reported, has no effect on topoisomerase 1, but produced 
catenated DNA complexes in the presence of topoisomerase 2, inducing only minimal topoisomerase 
2-mediated DNA cleavage [10]. Deoxyamphimedine was a potent cleaver of DNA in vitro as indicated 
by the increased intensity in the nicked (single strand break) and linear (double strand break) plasmid 
DNA bands. This activity was independent of the presence of topoisomerase 1 or 2. 
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Figure 3. Topoisomerase 1 and topoisomerase 2 DNA cleavage gels for amphimedine 
(Amph), neoamphimedine (Neo) and deoxyamphimedine (Deoxy). A) Plasmid DNA 
(supercoiled rf M13 mp 19 DNA) was used in the cleavage assay in the presence or 
absence of topoisomerase 1, with DMSO, 9-aminocamptothecin, 9AC (9 µM) that induces 
topoisomerase 1-mediated DNA single strand breaks, amphimedine (100 µM), 
neoamphimedine (100 µM), and deoxyamphimedine (100 µM). B) Plasmid DNA was used 
in the cleavage assay in the presence and absence of topoisomerase 2, etoposide (Etop,  
100 µM) that induces topoisomerase 2-mediated DNA double strand breaks, amphimedine 
(100 µM), neoamphimedine (100 µM), and deoxyamphimedine (100 µM). 
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Further evaluation in the cleavage assay showed deoxyamphimedine could fully cleave DNA under 
aerobic conditions in experiments carried out in water to which only dithiothreitol (DTT, a reducing 
agent) and DNA were added. Figure 4A shows results for all of the amphimedines in the absence or 
presence of 5 mM DTT. While no catenation was observed with neoamphimedine, there was a slight 
increase in the nicked DNA band. The amount of cleaved DNA observed was greatly increased with 
deoxyamphimedine in the presence of DTT. The amount of deoxyamphimedine-induced DNA 
cleavage observed increased with increasing amounts of DTT (Figure 4B). However, under hypoxic 
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conditions the amount of induced DNA cleavage was attenuated (Figure 4C). The extent of DNA 
cleavage increased with increasing deoxyamphimedine concentrations (Figure 4D) with detectable 
cleavage appearing at 5 µM and increasing to approximately 84% cleavage at 100 µM in this 
experimental system. Additional studies using the cleavage assay showed that deoxyamphimedine-
induced DNA cleavage exhibited a time dependency (data not shown), with complete cleavage of the 
substrate in the presence of 5 mM DTT within 30 minutes. Deoxyamphimedine also cleaved plasmid 
DNA, regardless of its topological state. Specific reaction conditions, such as high salt or temperature, 
will reverse DNA damage detectable from stabilized drug-top1-DNA complexes, but not ROS-induced 
DNA damage. These conditions did not reverse deoxyamphimedine-induced DNA damage (data  
not shown). 
 
Figure 4. Deoxyamphimedine dependence on DTT, oxygen and concentration. A) Plasmid 
DNA was incubated in the presence of DTT (5 mM), amphimedine (Amph, 100 µM), 
neoamphimedine (Neo, 100 µM), and deoxyamphimedine (Deoxy, 100 µM). B) Plasmid 
DNA was incubated in the presence of deoxyamphimedine (100 µM) with varying amounts 
of DTT (as shown). C) Plasmid DNA was incubated in the presence of DTT (5 mM) and 
deoxyamphimedine (100 µM) as indicated. Hypoxic conditions were induced in the last 2 
lanes by bubbling argon in the reaction vessel. D) Plasmid DNA was incubated in the 
presence or absence of DTT (5 mM) with varying amounts of deoxyamphimedine (0.1 µM, 
0.5 µM, 1 µM, 5 µM, 10 µM, 50 µM, 100 µM). Increase in cleaved plasmid DNA over 
control in this experiment was quantifiable at 5 µM (12%), 10 µM (14%), 50 µM (67%), 
and 100 µM (84%). 
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2.4. Protection of DNA from Deoxyamphimedine Cleavage 
 
Metal chelators and FeSO4 were used to determine if a Fenton type reaction could be responsible 
for deoxyamphimedine-induced DNA cleavage. Metal chelators were added to aerobic reactions 
containing deoxyamphimedine, DTT and DNA. DNA cleavage in the presence of deoxyamphimedine 
was not further stimulated when FeSO4 (100 µM) was added (data not shown). Ion coupled plasma-
mass spectrometry (ICP-MS) was performed on deoxyamphimedine in DMSO to determine if it bound 
to metal ions in solution. The results suggest that some metal binding may be occurring (data not 
shown). However, only slight protection from DNA cleavage was sporadically detectable in the 
presence of deferoxamine mesylate (up to 50 mM) and ferrozine (up to 100 µM) (Figure 5A) or EDTA 
(100 µM) (data not shown). Overall, the addition of metals or metal chelators did not strongly alter the 
DNA cleaving ability of deoxyamphimedine. 
To determine if reactive oxygen species played a role in deoxyamphimedine’s DNA cleavage, an 
anti-oxidant enzyme and radical scavengers were employed to attenuate DNA cleavage. Figure 5B 
shows that catalase (CAT) and benzoic acid (BA) were able to inhibit cleavage by deoxyamphimedine. 
Other radical scavengers, glutathione (GSH) and N-acetylcholine (NAC), also attenuated 
deoxyamphimedine-induced DNA cleavage (data not shown). Superoxide dismutase (SOD), which 
converts superoxide to H2O2, did not decrease deoxyamphimedine-induced DNA cleavage. No 
additional protection was detected when SOD was used with catalase when compared to catalase alone 
(data not shown). 
 
Figure 5. A) Effects of chelators on deoxyamphimedine (Deoxy)-induced DNA cleavage. 
Plasmid DNA was incubated in the absence or presence of deoxyamphimedine (100 µM), 
ferrozine (100 µM) and deferoxamine mesylate (100 µM). B) Anti-oxidant enzymes and 
radical scavenger protection of deoxyamphimedine induced DNA cleavage. Plasmid DNA 
was incubated in the presence of deoxyamphimedine (100 µM) and varying amounts of 
catalase (CAT) (88 u, 8.8 u, 0.88 u) or the free radical scavenger benzoic acid (BA)  
(8.8 mM, 0.88 mM, 0.088 mM). 
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2.5. Discussion 
Although amphimedine, deoxyamphimedine and neoamphimedine are chemically very similar (see 
Figure 1), our data shows that their minor structural differences significantly alter their biological 
activities. Amphimedine was relatively inactive compared to deoxyamphimedine and 
neoamphimedine, both of which demonstrated considerable DNA-directed activity. Amphimedine did 
not significantly intercalate DNA at the concentrations tested and was not cytotoxic at doses up to  
100 µM. Neoamphimedine and deoxyamphimedine displace EtBr from DNA, although 
deoxyamphimedine is more effective than neoamphimedine. Both deoxyamphimedine and 
neoamphimedine are cytotoxic, although by differing mechanisms. Deoxyamphimedine is a positively 
charged compound, which differentiates it from amphimedine and neoamphimedine. As mentioned 
above, it interacts with DNA avidly and is the most cytotoxic of the three amphimedines tested. 
Several other marine pyridoacridines (e.g., dercitin, cystodytin J, ascididemin and diplamine) have 
previously been shown to intercalate DNA [23-25]. 
Deoxyamphimedine facilitated DNA cleavage in vitro, unlike amphimedine or neoamphimedine. 
Under aerobic conditions, the reducing agent DTT was the sole requirement for full activity. Low 
oxygen conditions reduced the amount of DNA cleaved and the total absence of DTT yielded 
undetectable levels of DNA damage. The DNA cleavage was time dependent, requiring more time to 
reach maximal DNA damage than is typically needed by topoisomerase 1-DNA cleavable complex 
stabilizing drugs (DNA, topoisomerases and topoisomerase poisons form the ternary complex  
very rapidly).  
In our experimental systems, deoxyamphimedine produced results very similar to ascididemin, 
another pyridoacridine that produces damage to DNA through ROS [24,26]. Anti-oxidants and anti-
oxidant enzymes protected DNA from deoxyamphimedine-induced cleavage, indicating a ROS-
mediated mechanism. Extensive protection against DNA cleavage by the anti-oxidant enzyme catalase, 
suggested H2O2 as a likely intermediate ROS. In addition, anti-oxidants and reactive scavengers 
including glutathione, BHA, NAC and benzoic acid all protected against DNA damage. Therefore, the 
production of –OH most likely occurs. Previous work using electron paramagnetic resonance 
spectroscopy with ascididemin and analogs yielded a complex signal that indicated multiple 
iminoquinone radical species were likely formed [24]. We speculate that this would be the case for 
deoxyamphimedine as well. 
Quinones and iminoquinones are capable of redox cycling. One electron reduction of the quinone 
forms a reactive semiquinone, allowing electron transfer to other species [27]. Higher redox potential 
of quinone molecules has been correlated with increased DNA cleavage [18,28]. Moreover, evidence 
suggests that doxorubicin and daunorubicin, both with quinone moieties, owe some of their clinical 
activity to ROS generation [27,29-33]. We hypothesize that it is the iminoquinone portion of 
deoxyamphimedine that is responsible for the redox cycling and ROS generation. Redox cycling and 
ROS generation require a source of oxygen. Under hypoxic conditions the ability of 
deoxyamphimedine to cleave DNA diminishes. Direct reduction of deoxyamphimedine to the semi-
iminoquinone species likely facilitates the production of H2O2 and DNA damaging free radicals. It will 
be beneficial to further characterize the redox potential of deoxyamphimedine when more of it is 
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available, current supplies being exhausted. All together, these data strongly implicate ROS as the 
mediator of deoxyamphimedine-induced DNA damage.  
3. Experimental 
3.1. Chemicals and Reagents 
Isolation and chemical characterization of amphimedine, deoxyamphimedine and neoamphimedine 
have been described [11,34]; all were greater than 95% pure. They were isolated from two 
Xestospongia sp. sponges collected from Surigao, Philippines and Palau. All chemicals and reagents 
were obtained from Sigma Chemical Co. (St. Louis, MO, USA) or Baker Chemical Co. (Springfield, 
NJ, USA) unless otherwise noted. Drug standards were purchased from Sigma Chemical Co. 
Radioactive thymidine was purchased from New England Nuclear (Boston, MA, USA). Restriction 
enzymes and buffers were purchased from New England Biolabs (Ipswich, MA, USA). Radiolabeled 
(4.4 X 103 cpm/g) 3H replicative form (rf) of M13 mp19 was isolated by the alkaline lysis method as 
described [35,36]. Human topoisomerase 1 and topoisomerase 2 were isolated as described [36,37]. 
3.2. Assessment of DNA Intercalation 
DNA intercalation was measured as the ability of drug to displace ethidium bromide (EtBr) from 
DNA. Based on the protocol of McDonald et al. [25], 10 serial dilutions (nM-M) of drug were added 
with 0.5 M EtBr to 0.5 M salmon testes DNA (Sigma Chemical Co.) in a 96-well microtiter plate 
and incubated for 30 min at room temperature. A fluorimeter was used to quantify the fluorescence of 
each reaction, (280 nm excitation wavelength; displacement of EtBr was measured as a decreased 
fluorescence at 600 nm).  
3.3. Quantitation of DNA and Cleavage 
DNA cleavage assays were performed as previously described [10,36]. In brief, 20 µL volumes 
containing 50 mM Tris-HCl (pH 7.5), 85 mM KCl, 10 mM MgCl2, 0.5 mM EDTA, 30 g/mL bovine 
serum albumin (Atlanta Biologicals, Atlanta, GA), 2 mM DTT, 500 ng of radiolabeled and supercoiled 
rf M13 mp 19 DNA and 100-150 ng purified topoisomerase 1 or 80-120 ng purified topoisomerase 2 
were treated with 1-2 µL drug (in DMSO) and incubated at 30oC for 30 min. The reactions were 
stopped by the addition of 2 µL of 1.5 mg/mL proteinase K in 0.5% SDS and incubated at 37oC for  
60 min. The DNA was fractionated by electrophoresis in 0.8% agarose (containing 50 ng EtBr/mL 
TAE) to separate the nicked, linear, relaxed and supercoiled isomers.  
EtBr stained DNA was visualized by its fluorescence under UV light, and the bands were sliced out 
of the gel. To quantify the DNA in the bands the gel slices were placed in scintillation vials with 1 mL 
water, melted in a microwave oven and mixed with 10 mL Opti-Fluor (Packer Co., Meridien, CT, 
USA) while molten. Radioactivity determined by standard liquid scintillation counting [37]. The 
percentage of cleaved DNA, represented by radioactivity in the combined nicked and linear bands, was 
determined relative to the total radioactivity in the reactions, following subtraction of radioactivity due 
to endogenously cleaved DNA. The percentage of catenated DNA was determined similarly. All 
experiments were repeated three times, representative results are presented.  
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3.4. Cell Culture 
The human epidermoid-nasopharyngeal tumor cell line (KB), human melanoma cell line (SK-mel-
5), human breast cancer cell line (MCF7), human ovarian multi-drug resistant cell lines (A2780 and 
A2780AD), and Chinese hamster ovary cell lines (CHO): AA8 (wild type), EM9 (single strand break 
repair deficient) and xrs-6 (double strand break repair deficient) were used. KB, SK-mel-5, MCF7, 
EM9 and AA8 cell lines were purchased from ATCC, Rockville, MD). A2780 and A2780AD cell lines 
were provided by Dr. Jindrich Kopecek (University of Utah, UT, USA) and the xrs-6 cell line was a 
generous gift from Dr. Penny A. Jeggo and co-workers (University of Sussex, U.K.). All cell lines 
were maintained in Minimal Essential Medium alpha modification (-MEM), Atlanta Biologicals. 
CHO cell lines were supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals), and the 
others were supplemented with 2.5% FBS and 7.5% calf sera (Atlanta Biologicals), 100 u/mL 
penicillin and 100 g/mL streptomycin (Sigma Chemical Co.). Cells were grown at 37oC as 
monolayers in 75 cm2 culture flasks and detached with trypsin before seeding into microtiter  
culture plates.  
3.5. MTT Cell Cytotoxicity Assay 
Cytotoxicity was established in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay as performed by Mossman [38] and modified by others [22, 39, 40]. Drugs were 
dissolved in 100% DMSO at initial concentrations of 10 mM and serially diluted. The final 
concentration of DMSO in the cell culture wells was 1% or less. Cells were seeded in 200 µL of 
growth media in Corning 96-well microtiter plates at 30,000 cells/well (AA8), 40,000 cells/well (xrs-6 
or EM9), or 20,000 cells/well (human cell lines). Four hours after seeding, cells were treated, each 
dose in quadruplicate, with 2 µL of drug (CHO cell lines) or 1 µL of drug (all other cell lines). CHO 
cell lines were refed at 18 hours. After 72 hours, all cultures were refed with 100 µL McCoy’s medium 
and 11 µL MTT (5 mg/mL in PBS, pH 7.4) was added to each well. The plates were incubated for 4 
hours at 37oC. Viable cells reduced MTT to a purple formazan product that was solubilized by the 
addition of 100 µL DMSO to aspirated culture wells. The absorbance at 540 nm was measured for 
each well using a Bio-Rad MP450 plate reader (Bio-Rad, Hercules, CA). Following subtraction of 
absorbance from blank culture cells, the average absorbance for each set of drug-treated wells was 
compared to the average absorbance of the control wells to determine the fractional survival at any 
particular drug concentration. The inhibitory concentration 50 (IC50) was defined as the drug 
concentration that yielded a fractional survival of 50%. 
3.6. Time and Concentration Dependence of DNA Cleavage 
To determine the time and concentration dependency of deoxyamphimedine cleavage in vitro, DNA 
cleavage assays were performed as described above (3.3) using different time points of incubation  
(0 to 60 minutes) and increasing concentrations of deoxyamphimedine (0.1 to 500 µM).  
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3.7. DNA Cleavage Protection Assays 
Protection from deoxyamphimedine-induced DNA cleavage was determined as described [24]. 
Metal chelators (i.e. EDTA, ferrozine, deferoxamine mesylate), the metal salt, FeSO4, radical 
scavengers [i.e. glutathione (GSH), N-acetylcysteine (NAC) and benzoic acid (BA)] or anti-oxidant 
enzymes [i.e. catalase (CAT)] were added to reactions described above to further define the potential 
mechanisms of DNA cleavage.  
3.8. Assessment of DNA Cleavage under Hypoxic Conditions 
DNA cleavage reactions were carried out as described above (3.3); however, these reactions were 
modified to be hypoxic based on the work of Radisky et al. [41]. Drug and reaction mix containing 
DNA were bubbled with argon for several minutes prior to the addition of drug to the reaction mix. At 
this point, the reaction mix was bubbled under argon for 1 min, lids were closed and it was then 
incubated at 37 °C for 30 min before being run out on an agarose gel, as described above. 
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